Editor's Note This study by researchers at the Centers for Disease Control and Prevention finds that adverse reactions after the third dose of Pfizer-BioNTech’s COVID-19 vaccine were similar to those after the second dose. Of 12,591 participants who completed a survey after all three doses: 79.4% and 74.1% reported local…
Editor's Note ECRI, on September 30, announced a new partnership with the Food and Drug Administration (FDA) to improve the safety of medical devices through the use of safer materials. ECRI is developing safety reports for materials commonly used in implantable medical devices and assessing their possible effects on patients…
Editor's Note This study by Israeli researchers finds that restrictions implemented during COVID-19 dramatically altered daily routines and limited time spent outdoors, which resulted in deteriorating personal wellbeing. The analysis of 7,517 adults from 40 countries who were surveyed during the 2020 COVID-19 restrictions found that social restrictions impaired all…
Editor's Note The Food and Drug Administration (FDA) on September 22 amended the emergency use authorization (EUA) for Pfizer-BioNTech’s COVID-19 vaccine to allow for use of a single booster to be administered at least 6 months after completion of the primary series in those: 65 years of age and older…
Editor's Note COVID-19 vaccination requirements have caused some organizations to fire healthcare workers (HCWs) for noncompliance, and HCWs have quit over the policies, the September 17 Becker’s Hospital Review reports. Healthcare systems announcing resignations and terminations include the following: Morehead, Kentucky-based St Claire HealthCare has fired 23 HCWs for noncompliance…
Editor's Note The Food and Drug Administration (FDA), on September 20, identified Medtronic’s recall of its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device with Shield Technology as Class I, the most serious. The devices, which are used to treat brain aneurysms, were recalled because there is a risk…
Editor's Note In this study, Centers for Disease Control and Prevention (CDC) researchers report on the comparative effectiveness of COVID-19 vaccines against hospitalization of US adults without immunocompromised conditions. Included in the case-control analysis were 3,689 adults aged 18 years and older who were hospitalized at 21 US hospitals between…
Editor's Note The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older. The committee did vote to recommend approval of…
Editor's Note This study led by researchers at the University of Texas Southwestern Medical Center, Dallas, finds that although COVID-19’s effect on access to liver transplantation has been all-pervasive, minorities have been disproportionately affected—especially those with public insurance. During the initial wave of COVID-19, organ transplantation was classified as a…
Editor's Note The Joint Commission, on September 15, announced that the deadline to participate in the Institute for Safe Medication Practices’ (ISMP) Medication Safety Self Assessment for Perioperative Settings has been extended to December 10. The self-assessment helps those in perioperative settings see how well their organizations’ systems and practices…